Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2020 - 12 - 07 tags : Phase 2 save search
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
Published: 2020-12-07 (Crawled : 22:00) - globenewswire.com
AGIO | $31.67 -0.44% -0.44% 640K
|
Health Technology
|
| O: -9.8%
H: 0.0%
C: -6.89%
disease phase 3 phase 1 phase 2
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Published: 2020-12-07 (Crawled : 14:00) - globenewswire.com
SRPT | $124.25 6.09% 5.75% 1.5M
|
Health Technology
|
| O: -1.99%
H: 1.94%
C: -2.54%
positive results trial phase 2 duchenne
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
Published: 2020-12-07 (Crawled : 13:05) - globenewswire.com
KROS | $56.24 1.9% 1.68% 310K
|
Health Technology
|
| O: -0.36%
H: 2.91%
C: -2.8%
results trial phase 3 phase 1 phase 2 preclinical pre-clinical
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Published: 2020-12-07 (Crawled : 13:02) - globenewswire.com
ONCT | $8.545 -2.51% -0.11% 1.6K
|
Health Technology
|
| O: 48.5%
H: 23.29%
C: 0.76%
phase 3 phase 1 phase 2
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3501 -2.67% -2.77% 120K
|
Health Technology
|
| O: 0.0%
H: 2.47%
C: -19.01%
phase 3 phase 1 phase 2 t-cell
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -2.91%
H: 0.0%
C: -7.0%
trial phase 3 phase 1 phase 2 clinical hold
ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
Published: 2020-12-07 (Crawled : 12:01) - globenewswire.com
ALXO M | $16.22 4.65% 4.56% 260
|
Commercial Services
|
| O: -1.17%
H: 2.55%
C: -2.97%
cancer phase 2 agx148
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability
Published: 2020-12-07 (Crawled : 11:01) - globenewswire.com
HOOK | $0.85 11.11% 9.25% 280K
|
Health Technology
|
| O: 2.13%
H: 8.6%
C: 6.34%
cancer therapy treatment phase 3 phase 1 phase 2
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.